Outcomes of patients with advanced sarcoma enrolled in clinical trials of pazopanib in combination with histone deacetylase, mTOR, Her2, or MEK inhibitors.

Dembla, Vikas; Fu, Siqing; Wheler, Jennifer J.; Hong, David S.; Janků, Filip; Zinner, Ralph; Piha‐Paul, Sarina A.; Ravi, Vinod; Benjamin, Robert S.; Patel, Shreyaskumar; Somaiah, Neeta; Herzog, Cynthia E.; Karp, Daniel D.; Meric‐Bernstam, Funda; Subbiah, Vivek

doi:10.1200/jco.2016.34.15_suppl.11057

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two participants with ASPS in a pediatric phase 1 of pazopanib were reported to have stable disease on treatment [10]. The poster presentation of an abstract by Dembla et al [11] (though not the abstract) described a clinical response of lung metastases in a study participant with ASPS receiving pazopanib. An EORTC retrospective of the PALETTE study noted an individual with ASPS was among the 3.5% of study participants who stayed on pazopanib for over 2 years [12].…”

Section: Discussionmentioning

confidence: 99%

Metastatic Alveolar Soft Part Sarcoma Responsive to Pazopanib after Progression through Sunitinib and Bevacizumab: Two Cases

Read

Williams

2016

Case Rep Oncol

View full text Add to dashboard Cite

Alveolar soft part sarcoma (ASPS) is a rare soft tissue sarcoma with a propensity for lung metastases and indolent progression. ASPS is not responsive to chemotherapy, but there are case reports and small series describing benefit from drugs targeting the VEGF pathway. These drugs include sunitinib, cediranib and bevacizumab. There is no established second-line treatment for persons with ASPS progressing through first-line targeted therapy. We report two individuals with metastatic ASPS who obtained disease stabilization from sunitinib lasting over a year. After subsequent progression through sunitinib and second-line bevacizumab, both individuals again had disease response and subsequent stabilization from pazopanib.

show abstract

Section: Discussionmentioning

confidence: 99%

Metastatic Alveolar Soft Part Sarcoma Responsive to Pazopanib after Progression through Sunitinib and Bevacizumab: Two Cases

Read

Williams

2016

Case Rep Oncol

View full text Add to dashboard Cite

show abstract

“…TP53 mutations may predict response to pazopanib, but further investigation is need to validate this, as well as other biomarkers. 109,110 Hypertension has not proven a reliable biomarker to predict response to pazopanib. 111 In 2012, pazopanib was FDA approved for the treatment of STS progressed on prior anthracycline-based therapy, with the exception of LPS histology.…”

Section: Trabectedinmentioning

confidence: 99%

Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations

Tseng

2017

Ther Adv Med Oncol

View full text Add to dashboard Cite

Soft tissue sarcoma (STS) is a biologically heterogeneous malignancy with over 50 subtypes. Historically, there have been few systemic treatment options for this relatively rare disease. Traditional cytotoxic agents, such as anthracyclines, alkylating agents, and taxanes have limited clinical benefit beyond the first-line setting; across all high-grade STS subtypes, median overall survival remains approximately 12–18 months for advanced metastatic disease. The development of targeted therapies has led to recent US Food and Drug Administration approval of four new treatments for high-grade STS in the advanced metastatic setting. Among these, olaratumab is most notable for its improvement in overall survival for patients with anthracycline-naïve disease. Further progress in STS management will rely on novel trial design, subtype-specific therapies and validation of biomarkers to tailor therapy. Immunotherapy has shown promise as a new, but yet undiscovered frontier in the management of STS.

show abstract

Outcomes of patients with advanced sarcoma enrolled in clinical trials of pazopanib in combination with histone deacetylase, mTOR, Her2, or MEK inhibitors.

Cited by 2 publications

References 0 publications

Metastatic Alveolar Soft Part Sarcoma Responsive to Pazopanib after Progression through Sunitinib and Bevacizumab: Two Cases

Metastatic Alveolar Soft Part Sarcoma Responsive to Pazopanib after Progression through Sunitinib and Bevacizumab: Two Cases

Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations

Contact Info

Product

Resources

About